Literature DB >> 21751830

The fatal love of forms.

Bruce Hugman.   

Abstract

Mesh：

Year:  2011        PMID： 21751830     DOI： 10.2165/11595130-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  4 in total

1.  The New Zealand Intensive Medicines Monitoring Programme.

Authors:  D M Coulter
Journal:  Pharmacoepidemiol Drug Saf       Date:  1998-03       Impact factor: 2.890

Review 2.  Improving the reporting of adverse drug reactions in the hospital setting.

Authors:  Richard Pushkin; Lynda Frassetto; Candy Tsourounis; Eleanor S Segal; Stephanie Kim
Journal:  Postgrad Med       Date:  2010-11       Impact factor: 3.840

Review 3.  Determinants of under-reporting of adverse drug reactions: a systematic review.

Authors:  Elena Lopez-Gonzalez; Maria T Herdeiro; Adolfo Figueiras
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228
  4 in total
  3 in total

1.  Protecting the people?: risk communication and the chequered history and performance of bureaucracy.

Authors:  Bruce Hugman
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606

2.  Descriptive analysis of postmarket surveillance data for hip implants.

Authors:  Josep Pane; Katia M C Verhamme; Irene Rebollo; Miriam C J M Sturkenboom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-03-03       Impact factor: 2.890

3.  Increasing Patient Engagement in Pharmacovigilance Through Online Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reporting for the Essure Device in the US.

Authors:  Chi Y Bahk; Melanie Goshgarian; Krystal Donahue; Clark C Freifeld; Christopher M Menone; Carrie E Pierce; Harold Rodriguez; John S Brownstein; Robert Furberg; Nabarun Dasgupta
Journal:  Pharmaceut Med       Date:  2015-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.